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Abstract
Background: Loss of basal forebrain cholinergic neurons is attributable to the proapoptotic signaling induced by
nerve growth factor receptor (NGFR) and may link to Alzheimer’s disease (AD) risk. Only one study has investigated
the association between NGFR polymorphisms and the risk of AD in an Italian population. Type 2 diabetes mellitus
(DM) may modify this association based on previous animal and epidemiologic studies.
Methods: This was a case-control study in a Chinese population. A total of 264 AD patients were recruited from
three teaching hospitals between 2007 to 2010; 389 controls were recruited from elderly health checkup and
volunteers of the hospital during the same period of time. Five common (frequency≥5%) haplotype-tagging single
nucleotide polymorphisms (htSNPs) were selected from NGFR to test the association between NGFR htSNPs and
the risk of AD.
Results: Variant NGFR rs734194 was significantly associated with a decreased risk of AD [GG vs. TT copies: adjusted
odds ratio (OR) = 0.43, 95% confidence interval (CI) = 0.20-0.95]. Seven common haplotypes were identified. Minor
haplotype GCGCG was significantly associated with a decreased risk of AD (2 vs. 0 copies: adjusted OR = 0.39, 95%
CI = 0.17-0.91). Type 2 DM significantly modified the association between rs2072446, rs741072, and haplotype
GCTTG and GTTCG on the risk of AD among ApoE ε4 non-carriers (Pinteraction < 0.05).
Conclusion: Inherited polymorphisms of NGFR were associated with the risk of AD; results were not significant
after correction for multiple tests. This association was further modified by the status of type 2 DM.
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Introduction
Dementia is a degenerative brain syndrome character-
ized by decline or loss in cognitive function [1]. About
30 million elders suffered from dementia worldwide in
2008 estimated by Alzheimer’s Disease International.
Alzheimer’s disease (AD) is the most common causes of
dementia and was the fifth leading cause of death for
those aged 65 or older in the United States in 2006 [1].
In Taiwan, more than 160,000 people were demented in
2009 [2] and the number of AD patients keeps raising
in many aging populations.
Degeneration of basal forebrain cholinergic neurons
(BFCN) has shown to modulate cognitive function in AD
patients [3,4]. Nerve growth factor receptor (NGFR, also
called p75
NTR) is one of the receptors of NGF and is
expressed at the end of cholinergic axon [5,6]. The gene
encoding NGFR is located on chromosome 17q21-q22. In
normal brain, NGFR regulates tyrosine kinase receptor
type 1 (TrkA), another receptor of NGF, and induces the
signaling of neuronal cell survival [7,8]. In contrast, in AD
brain, NGFR acts as a proapoptotic receptor in neuron
cell death via binding to amyloid-beta (Ab), NGF, or
proNGF [9,10]. As a whole, NGFR plays multiple roles
(survival and apoptosis) in human brain, dependent on the
cellular context.
* Correspondence: karenchen@ntu.edu.tw
1Institute of Epidemiology and Preventive Medicine, College of Public Health,
National Taiwan University, Taipei, Taiwan
Full list of author information is available at the end of the article
Cheng et al. Journal of Negative Results in BioMedicine 2012, 11:5
http://www.jnrbm.com/content/11/1/5
© 2012 Cheng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.So far, only one study assessed the association between
NGFR genetic polymorphisms and the risk of AD in an
Italian population [11]. Cozza et al. found that variant
rs2072446 was associated with a significantly decreased
risk of familial AD [additive model: odds ratio (OR) =
0.28] [11]. However, no association was observed for other
NGFR SNPs (rs741072, rs2072446, rs2072445, and
rs734194) and the risk of sporadic AD [11]. In addition,
type 2 DM has been related to the change of NGFR
expression in rat brain [12] and cognitive impairment and
dementia in the elderly [13-15]. However, no study has
explored how type 2 DM affects the association of NGFR
polymorphisms with the risk of AD.
NGFR plays an important role in neuronal survival and
apoptosis, which may be related to AD pathogenesis.
However, only one study explored the association between
sequence variants of NGFR and AD in a Caucasian popu-
lation. Therefore, we hypothesized that NGFR genetic
polymorphisms were associated with the risk of AD in
Chinese population. In addition, NGFR may involve in
diabetic encephalopathy through neuronal apoptosis.
Therefore, this study further investigated how type 2 DM
modified the association of NGFR genetic polymorphisms
with the risk of AD.
Materials and methods
Study Population
This was a case-control study. A total of 295 sporadic AD
patients were recruited from neurology clinic of three
teaching hospitals in northern Taiwan from 2007 to 2010.
Healthy controls (n = 406) were recruited from elderly
health checkup and volunteers during the same period of
time. All participants were Chinese aged 60 years or older.
Participants with the following diseases were excluded:
hemorrhagic stroke, organic brain tumor, central nervous
system diseases (e.g., Parkinson’s disease), depression, cer-
ebral infarction, and dementia other than AD (e.g., vascu-
lar dementia and mixed-type dementia, etc.). This study
was approved by the institutional review board of each
hospital and College of Public Health, National Taiwan
University. Written informed consent was obtained from
each study participant. The consent from the legal guar-
dian/next of kin was obtained when patients had serious
cognitive impairment.
A questionnaire was administered to collect informa-
tion on demography, comorbidity (e.g., DM and stroke),
life style (e.g., cigarette smoking, alcohol, tea or coffee
consumption, and exercise); and family history. Blood
sample was collected in a tube containing EDTA from
each participant. Genomic DNA was extracted by using
QuickGene-Mini80 kit (Fujifilm, Tokyo, Japan). After
further exclusion of participants without blood samples,
a total of sporadic 264 AD patients and 389 controls
were included for data analysis.
Dementia Evaluation
This study included only late-onset (age ≧ 60) non-familial
AD. One neurologist at each hospital performed clinical
examination to screen potential dementia cases. Mini-
Mental State Examination (MMSE) [16] and Clinical
D e m e n t i aR a t i n g( C D R )[ 1 7 ]w e r eu s e dt oa c c e s st h e i r
cognitive function. The diagnosis of dementia was done by
using Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth edition (DSM-IV) [18]. Head images, com-
puted tomography and magnetic resonance imagings,
were taken to exclude organic lesions. Diagnosis of AD
was further determined by National Institute of Neurologi-
cal and Communicative Diseases and Stroke - Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) Alzheimer’s Criteria [19]. Short Portable Mental
Status Questionnaire [20] was used to assess cognitive
function in controls to exclude participants with possible
dementia and other mental disorders.
Selection of Single Nucleotide Polymorphisms (SNP) and
Genotyping Assay
Eleven common SNPs (frequency ≧ 5%) in NGFR were
identified by using Han Chinese Beijing, China (CHB)
genotype data from the International HapMap Project
http://hapmap.ncbi.nlm.nih.gov/. Modified Gabriel et al.
algorithm [21,22] was used to define haplotype block by
using Haploview program http://www.broadinstitute.org/
haploview/haploview. A total of 5 htSNPs (rs2072445,
rs2072446, rs734194, rs741072, and rs741073) with an r
2
of 0.87 were selected in NGFR gene by tagSNP program
[23] (Table 1). Five SNPs spanning NGFR formed one
block.
Genotypes of NGFR and Apolipoprotein E (ApoE ε4)
SNPs (rs429358 and rs7412) were determined by Taq-
Man
® Genomic Assays [24] using ABI 7900 HT fast real-
time PCR system (Applied Biosystems, CA, USA). Geno-
typing success rate was greater than 95% for each SNP.
Duplicate of 5% internal samples were selected for quality
control purpose and the concordance rate reached 100%
for each SNP.
Statistical Analyses
Comparison of demographic characteristics between
cases and controls were examined by using Student’st
tests for normally-distributed continuous variables and
chi-square tests for categorical variables.
Hardy-Weinberg equilibrium (HWE) test was performed
for each SNP among controls to check genotyping error
and selection bias. Partition-ligation-expectation-maximiza-
tion algorithm was utilized to estimate haplotype frequen-
cies by using tagSNP program [23].
To control for the confounding effect of age, fre-
quency matching was used to match cases and controls
on age within an interval of 5 years. The multivariate
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estimate SNP- and haplotype-specific odds ratio (OR)
and 95% confidence intervals (CI) for AD in participants
carrying either 1 or 2 versus 0 copies of minor allele of
each SNP and each multilocus haplotype. Potential con-
founders adjusted in the models included age, sex, and
ApoE ε4 status. Stratified analyses were performed by
ApoE ε4 status [25,26] and sex [27,28] because they
have been related to the risk of AD. To control for type
I error, the false discovery rate (FDR) and the single
multiple-degree-of-freedom global test for the associa-
tion between NGFR haplotypes and the risk of AD was
performed. Given a significant global test, haplotype-
specific tests can provide some guidance as to which
variant(s) contribute to the significant global test.
Vascular risk factors (type 2 DM, hypertension, and
hyperlipidemia) and ApoE ε4 status were known risk
factors of dementia. Likelihood ratio test was used to
evaluate the effect modification by each vascular risk
factor on the association between NGFR polymorphisms
and the risk of AD by comparing the model with main
effects and interaction terms to the model with main
effects only under the assumption of dominant model.
Stratified analysis by type 2 DM status or ApoE ε4 status
was performed to estimate OR for NGFR genetic poly-
morphisms and the risk of AD. All statistical tests were
two-sided. SAS version 9.1 (SAS Institute, Cary, NC,
USA) was used for statistical analyses.
Results
Characteristics of study population
A total of 264 AD cases and 389 controls were recruited
in this study. As compared with controls, AD cases were
older (79 vs. 72 years old), included more women (65%
vs. 53%), had a lower education level (elementary school:
50 vs. 10 years), more with the history of type 2 DM
(18% vs. 13%), fewer with the history of hypertension
(39% vs. 53%) or hyperlipidemia (18% vs. 30%), and
more were ApoE ε4 carriers (40% vs. 14%, Table 1).
Haplotype-tagging SNPs in NGFR
Five htSNPs were selected from 11 common (frequency
≧ 5%) SNPs spanning NGFR formed one block, which
was determined by the modified Gabriel et al. algorithm
[21,22] (Figure 1). None of the NFGR SNPs was out of
HWE (Table 2). The internal quality-control specimens
did not show evidence of genotyping error as well. The
minor allele frequencies (MAFs) of rs734194 (0.19 vs.
0.29) and rs741072 (0.41 vs. 0.30) were slightly different
between HapMap data and our controls. Other SNPs
(rs2072445 and rs2072446) showed similar frequencies.
NGFR SNPs and AD risk
Variant rs734194 was significantly associated with a
decreased risk of AD (GG vs. TT: OR = 0.43, 95% CI =
0.20-0.95) (Table 3). rs734194 remained significantly
associated with an increased risk of AD under the
assumption of additive model (OR = 0.71, 95% CI =
0.52-0.98, data not shown). After controlling for FDR,
no significant association was observed for NGFR SNPs
and the risk of AD.
NGFR haplotypes and AD risk
S e v e nc o m m o n( f r e q u e n c y ≥5%) haplotypes, composed
by 5 htSNPs, were identified with a cumulative fre-
quency of 97.3% in controls (Figure 1 & Table 4). Figure
1 demonstrated the LD structure by using the genotype
data of controls in this study. The global P for the asso-
ciation between haplotypes and the risk of AD was 0.27.
Participants carrying two copies of the minor Hap1
GCGCG had a significantly decreased risk of AD (OR =
0.39, 95% CI = 0.17-0.91). No haplotype was associated
with AD risk under the assumption of additive model
(data not shown). After correction for multiple tests by
using FDR, significant association between NGFR poly-
morphisms and AD risk did not retain.
Effect of ApoE ε4 status
The ApoE ε4 carriers had a significantly increased risk of
AD (OR = 4.45, 95% CI = 2.93-6.75) after adjusting for
age and sex. The significant association remained after
stratified by sex (male: OR = 3.45, 95% CI = 1.82-6.56;
Table 1 Characteristics of the study population
Alzheimer’s disease
(n = 264)
Controls
(n = 389)
Mean ± SD
Age (years) 79 ± 7 73 ± 6
n (%)
Female 172 (65%) 207 (53%)
Education
Elementary 132 (50%) 40 (10%)
High school 93 (35%) 160 (41%)
College and above 39 (15%) 189 (49%)
Cigarette smoking
Never 204 (77%) 321 (83%)
Former 42 (16%) 56 (14%)
Current 18 (7%) 12 (3%)
Alcohol consumption
Never 230 (87%) 349 (90%)
Former 24 (9%) 13 (3%)
Current 10 (4%) 27 (7%)
Type 2 diabetes 48 (18%) 51 (13%)
Hypertension 103 (39%) 205 (53%)
Hyperlipidemia 48 (18%) 115 (30%)
ApoEε `4 carriers 107 (40%) 55 (14%)
Abbreviation: ApoE, Apolipoprotein E gene; SD, standard deviation.
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shown).
Effect modification by vascular risk factors
Among the vascular risk factors (hypertension, type 2
DM, and hyperlipidemia), type 2 DM was the only factor
significantly modifying the association between NGFR
polymorphisms (rs2072446, rs741072, Hap2, and Hap5)
and the risk of AD. After stratification by type 2 DM sta-
tus, significant associations were observed in some sub-
groups. Because ApoE ε4 status is an important risk
factor for AD, we assess the effect modification by type 2
DM for ApoE ε4 carriers and non-carriers separately.
For NGFR SNPs, in ApoE ε4 non-carriers without type 2
DM, variant rs2072446 was associated with an increased
risk of AD (TT+TC vs. CC: OR = 2.18, 95% CI = 1.19-
4.00) (Table 5). In contrast, variant rs734194 was asso-
ciated with a decreased risk of AD (OR = 0.28, 95% CI =
0.08-0.98, Table 5) among diabetic ApoE ε4 non-carriers.
Significant interactions were observed between type 2 DM
and NGFR rs2072446 and rs741072 on the risk of AD
among ApoE ε4 non-carriers (Pinteraction = 0.007 and 0.04,
Table 5). Except the interaction between type 2 DM and
NGFR rs2072446 among ApoE ε4 non-carriers, other
results were not significant after controlling for FDR.
For NGFR haplotypes, among ApoE ε4 non-carriers, dia-
betic patients carrying minor Hap1 GCGCG had a
decreased risk of AD (1 or 2 copies vs. 0 copies: OR =
0.28, 95% CI = 0.08-0.97, Table 6). In addition, among
ApoE ε4 non-carriers, non-diabetic patients carrying
minor Hap5 GTTCG were associated with a 2.12-fold
increased risk of AD (95% CI = 1.13-3.99, Table 6).
Among ApoE ε4 non-carriers, type 2 DM significantly
modified the association of Hap2 and Hap5 with AD risk
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Figure 1 NGFR gene linkage disequilibrium (LD) plot. The plot
was generated by genotype data from this study by HaploView
program. The level of pairwise D’, which indicated the degree of
linkage disequilibrium between two SNPs, was shown in the linkage
disequilibrium structure in gray scale. The level of pairwise r
2, which
indicated the degree of correlation between two SNPs, was the
number in the cell of the LD plot. Five common (frequency ≧ 5%)
haplotypes were identified. Modified Gabriel et al. algorithm was
used to define the haplotype block and 5 htSNPs formed one block.
Table 2 Characteristics of NGFR haplotype-tagging SNPs
SNP1 SNP2 SNP3 SNP4 SNP5
rs2072445 rs2072446
(Ser205Leu)
rs734194 rs741072 rs741073
Nucleotide change G®TC ®TT ®GC ®TG ®A
Location Intron Exon 3’UTR 3’UTR 3’UTR
HapMap CHB
MAF 0.09 0.15 0.19 0.41 0.25
Controls
MAF 0.07 0.11 0.29 0.30 0.24
HWE P value 0.13 0.66 0.97 0.35 0.12
Cases
MAF 0.08 0.11 0.25 0.34 0.25
HWE P value 0.17 0.72 0.57 0.21 0.37
Abbreviations: HWE, Hardy-Weinberg equilibrium; UTR, untranslated region; MAF, minor allele frequency; CHB, Han Chinese in Beijing.
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nificant after controlling for FDR.
Disscusion
This is the first study exploring the association between
NGFR polymorphisms and the risk of AD by using 5
htSNPs. We found that NGFR rs734194 was significantly
associated with a decreased risk of AD, but this was not
observed in the only previous study in an Italian popula-
tion [11]. Possible reasons for the inconsistent findings
between the Italian study [11] and ours include differences
in sample size (Cozza et al. vs. ours, sporadic AD: 151 vs.
264, controls: 97 vs. 389), case selection (not available vs.
incident cases), race (Italian vs. Chinese), study time per-
iod (not available vs. 2007 to 2010), mean age (AD: 65 vs.
79, controls: 64 vs. 73), and SNPs selected (4 functional
SNPs vs. 5 htSNPs). This is also the only Asian study up
to date. In addition, no significant association was
observed for NGFR rs2072445 (in intron), rs2072446 (in
exon), and rs741072 [in 3’ untranslated region (UTR)],
which is consistent with the findings of the Italian study
[11]. rs741073 has not been explored for AD risk pre-
viously and was not associated with AD risk in our study.
Although 5 htSNPs are in strong linkage disequilibrium
(LD; i.e., high pairwise D’ as shown in dark gray, Figure 1)
and located within the same haplotype block, the pairwise
correlation (r
2) between rs734194 (SNP3) and any other
SNP is quite low (SNP1:0.02, SNP2: 0.04, SNP4: 0.20,
SNP5: 0.10, Figure 1).
Cholinergic hypothesis [3,4] has been used to elucidate
the role of NGFR in AD pathogenesis because of selective
loss of BFCN observed in AD patients. That is, elevated
expression of NGFR and decreased TrkA may activate
neuron apoptosis [29,30]. In addition, the binding of Ab
[31-33] and proNGF [9,34] to NGFR also induce neuron
apoptosis. rs734194 is located on 3’ UTR and thus plays
an important role in regulating the mRNA stability and
translational efficiency. Therefore, variations in rs734194
may reduce the expression of NGFR or the binding of
NGF, Ab,o rp r o N G Ft oNGFR, which inactivates the
neuron apoptotic signaling and leads to decreased risk of
AD. It is also possible that the variations of rs734194
decrease the secretion of NGFR on BFCN and thus
reduce the interaction of NGFR with Ab and proNGF,
which lower the neurotoxicity and apoptosis of BFCN.
All together, these mechanisms may explain the protec-
tive effect of NGFR rs734194 on the risk of AD observed
in this study.
Table 3 NGFR SNPs and the risk of Alzheimer’s
Co-dominant model
SNP 0 copies 1 copy 2 copies
Case/control OR Case/control OR (95% CI) p Case/control OR (95% CI) p
rs2072445 223/337 1.00 41/48 1.31 (0.76-2.28) 0.98 0/4 NA
rs2072446 208/306 1.00 52/79 1.43 (0.86-2.37) 0.60 4/4 3.32 (0.65-16.85) 0.22
rs734194 146/196 1.00 103/160 0.79 (0.52-1.20) 0.48 15/33 0.43 (0.20-0.95) 0.06
rs741072 110/157 1.00 118/192 1.02 (0.67-1.56) 0.67 36/40 1.10 (0.59-2.06) 0.64
rs741073 145/222 1.00 105/151 1.04 (0.69-1.57) 0.26 14/16 2.04 (0.82-5.09) 0.13
All models were adjusted for age, sex, education, and ApoEε `4 status.
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
Table 4 NGFR haplotypes and the risk of Alzheimer’s disease
Haplotype Frequency
among controls
(%)
Co-dominant model
0 copies 1 copy 2 copies
Case/control OR Case/control OR (95% CI) p Case/control OR (95% CI) p
Hap1: GCGCG 27.8 148/203 1.00 105/156 0.82 (0.54-1.25) 0.36 11/30 0.39 (0.17-0.91) 0.03
Hap2: GCTTG 21.9 159/234 1.00 90/140 0.94 (0.61-1.47) 0.79 15/15 1.01 (0.42-2.42) 0.99
Hap3: GCTTA 11.5 205/305 1.00 56/78 1.09 (0.65-1.84) 0.74 3/6 1.38 (0.27-6.97) 0.70
Hap4: GCTCA 11.3 197/304 1.00 65/81 1.37 (0.83-2.27) 0.22 2/4 0.94 (0.11-7.94) 0.95
Hap5: GTTCG 10.3 213/312 1.00 47/74 1.37 (0.81-2.33) 0.23 4/3 3.59 (0.66-19.42) 0.14
Hap6: GCTCG 8.9 217/323 1.00 46/63 0.97 (0.54-1.73) 0.92 1/3 0.18 (0.01-5.26) 0.32
Hap7: TCTCG 5.6 230/347 1.00 34/40 1.15 (0.63-2.12) 0.65 0/2 NA
Global test P = 0.27
All models were adjusted for age, sex, education, and ApoE e4 status.
Global test was testing for the null hypothesis that none of the haplotype was associated with AD risk.
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
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ciated with a decreased risk of AD. rs734194 is the only
SNP carrying the variant allele in Hap1. Therefore, the
significant association of Hap1 and AD may be attribu-
table to rs734194. It is also possible that other rare poly-
morphisms not analyzed here are responsible for the
association observed. Our finding was not comparable
to the Italian study [11] because fewer SNPs were
selected and no significant association was observed for
NGFR haplotypes in that study.
This study found that type 2 DM significantly modified
the association between NGFR polymorphisms and the
risk of AD in ApoE ε4 non-carriers. It is possible that type
2 DM modifies the association between NGFR and AD via
the following mechanisms: (1) hyperglycemia [35-37], (2)
altered insulin level and sensitivity in the brain [13,38-40],
and (3) diabetes-related vascular diseases, e.g., hyperten-
sion and arterial disease [41]. In addition, ApoE ε4 status
affects cholesterol metabolism and may act together with
DM to modulate the risk of AD [42-44]. The significant
effect modification was only observed in ApoE ε4 non-car-
riers, which may be due to the counteracting effect
between ApoE ε4 allele (increase AD risk) and variant of
NGFR (protective effect) on AD risk.
This study has some strengths. No study has investi-
gated the role of NGFR polymorphisms on the risk of
Table 5 Effect modification by type 2 diabetes on the association between NGFR genotype and the risk of Alzheimer’s
disease stratified by ApoEε `4 status
NGFRnon-variant carriers NGFR variant carriers Pinteraction
Case/control OR Case/control OR (95%CI)
ApoEε `4 non-carriers
rs2072445
Diabetes 25/40 1.00 6/4 5.53 (0.53-57.61)
Without diabetes 104/250 1.00 20/35 1.43 (0.70-2.92) 0.16
rs2072446
Diabetes 26/26 1.00 5/18 0.48 (0.12-1.98)
Without diabetes 89/227 1.00 35/58 2.18 (1.19-4.00) 0.007*
rs734194
Diabetes 23/23 1.00 8/21 0.28 (0.08-0.98)
Without diabetes 62/144 1.00 62/141 0.87 (0.52-1.45) 0.14
rs741072
Diabetes 8/21 1.00 23/23 2.97 (0.91-9.74)
Without diabetes 56/113 1.00 68/172 0.85 (0.50-1.43) 0.04
rs741073
Diabetes 14/27 1.00 17/17 1.84 (0.57-5.89)
Without diabetes 71/154 1.00 53/131 0.96 (0.57-1.61) 0.39
ApoE ε4 carriers
rs2072445
Diabetes 12/5 1.00 4/1 NA
Without diabetes 81/38 1.00 10/11 0.49 (0.16-1.46) NA
rs2072446
Diabetes 13/4 1.00 3/2 NA
Without diabetes 79/44 1.00 12/5 1.49 (0.36-6.21) NA
rs734194
Diabetes 7/3 1.00 9/3 2.55 (0.20-33.18)
Without diabetes 52/25 1.00 39/24 0.63 (0.28-1.46) 0.69
rs741072
Diabetes 11/4 1.00 5/2 2.09 (0.15-29.98)
Without diabetes 35/19 1.00 56/30 1.13 (0.47-2.69) 0.93
rs741073
Diabetes 8/5 1.00 8/1 NA
Without diabetes 51/31 1.00 40/18 1.24 (0.54-2.86) NA
All models were adjusted for age, sex, and education.
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
*Result remained significant after controlling for FDR.
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Alzheimer’s disease stratified by ApoEε `4 status
NGFR variant non-carriers NGFR variant carriers Pinteraction
Case/control OR Case/control OR (95%CI)
ApoEε `4 non-carriers
Hap1: GCGCG
Diabetes 23/23 1.00 8/21 0.28 (0.08-0.97)
Without diabetes 64/151 1.00 60/134 0.90 (0.53-1.51) 0.12
Hap2: GCTTG
Diabetes 15/29 1.00 17/15 2.79 (0.83-9.43)
Without diabetes 83/173 1.00 41/112 0.73 (0.42-1.26) 0.04
Hap3: GCTTA
Diabetes 22/34 1.00 9/10 1.17 (0.30-4.51)
Without diabetes 95/220 1.00 29/65 1.11 (0.57-2.14) 0.94
Hap4: GCTCA
Diabetes 22/36 1.00 9/8 1.91 (0.42-8.78)
Without diabetes 93/217 1.00 31/68 1.12 (0.59-2.11) 0.43
Hap5: GTTCG
Diabetes 26/27 1.00 5/17 0.50 (0.12-2.09)
Without diabetes 92/232 1.00 32/53 2.12 (1.13-3.99) 0.01
Hap6: GCTCG
Diabetes 26/39 1.00 5/5 2.50 (0.32-19.61)
Without diabetes 111/234 1.00 13/51 0.48 (0.21-1.10) 0.06
Hap7: TCTCG
Diabetes 25/41 1.00 6/3 7.15 (0.55-93.39)
Without diabetes 109/257 1.00 14/28 1.10 (0.48-2.54) 0.23
ApoEε4 carriers
Hap1: GCGCG
Diabetes 7/3 1.00 9/3 2.53 (0.19-33.57)
Without diabetes 52/25 1.00 39/24 0.64 (0.28-1.48) 0.71
Hap2: GCTTG
Diabetes 12/4 1.00 4/2 2.17 (0.13-35.20)
Without diabetes 48/28 1.00 43/21 1.04 (0.42-2.57) 0.82
Hap3: GCTTA
Diabetes 15/6 1.00 1/0 NA
Without diabetes 72/40 1.00 19/9 1.43 (0.47-4.31) NA
Hap4: GCTCA
Diabetes 9/5 1.00 7/1 NA
Without diabetes 70/41 1.00 21/8 1.49 (0.48-4.60) NA
Hap5: GTTCG
Diabetes 13/4 1.00 3/2 NA
Without diabetes 80/44 1.00 11/5 1.48 (0.35-6.26) NA
Hap6: GCTCG
Diabetes 13/4 1.00 3/2 NA
Without diabetes 66/41 1.00 25/8 2.42 (0.74-7.95) NA
Hap7: TCTCG
Diabetes 12/5 1.00 4/1 NA
Without diabetes 82/39 1.00 9/10 0.53 (0.16-1.72) NA
All models were adjusted for age, sex, and education.
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
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Page 7 of 9AD using a set of representative htSNPs and their corre-
sponding haplotypes. In this study, 5 htSNPs were
selected via a systematic approach and captured over
85% of genetic information in NGFR (estimated by
tagSNP program). In contrast, the only prior study [11]
assessed 4 NGFR SNPs, which capture only 14% of
genetic information in the gene. Second, the sample size
of our study is larger than the Italian study (Cozza et al.
vs. ours, sporadic AD: 151 vs. 264, controls: 97 vs. 389).
In addition, this study has over 90% power to detect an
OR of 0.43 for the main effect and 78% power to detect
an OR of 0.28 for the interaction between NFGR and
type 2 DM on the risk of AD. Third, no study has
assessed this association in Chinese population and
identified NGFR SNPs representative for this ethnic
group. Last, the use of brain image increased the validity
of AD ascertainment and reduced misclassification of
disease subtypes.
This study has some limitations. DM status was self-
reported and thus may be biased. However, in our ques-
tionnaire, this information was further confirmed by
asking if there was a previous diagnosis or taking medi-
cations for type 2 DM after seeing a doctor. Because
DM is a major disease, participants’ recall of DM diag-
nosis and their awareness of DM should be relatively
accurate [45-47]. As a whole, the chance of recall bias
was low.
In summary, this study found that NGFR htSNPs and
haplotypes were associated with AD risk. Type 2 DM
significantly modified the association between NGFR
polymorphisms and the risk of AD in ApoE ε4 non-car-
riers. Although these findings did not reach statistical
significance after correction for multiple tests, it is pos-
sible that the NFGR polymorphisms were associated
with familial AD. This is because NGFR rs2072446 was
associated with a decreased risk of familial AD in the
Italian study [11]. Most of sporadic AD cases are ApoE
ε4 non-carriers (60%) observed in this and other studies,
therefore, our findings shed light on the importance of
identifying genetic markers in ApoE ε4 non-carriers.
Future large studies are warranted to confirm our
findings.
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